Insulet Q4 Revenue Hits $784M with 29% Growth; 2028 Closed-Loop System Planned
Insulet reported Q4 revenue of $784 million, up 29% in constant currency, driving full-year revenue past $2.7 billion. The company expanded its US prescriber base by approximately 28% to over 30,000, while heavy R&D investment and anniversarying key launches signal slower growth in 2026 ahead of its planned 2028 closed-loop system.
1. Revenue Performance
Insulet closed Q4 with $784 million in revenue, marking 29% constant currency growth, and pushed full-year revenue past $2.7 billion. Growth was fueled by record new customer starts in both US and international markets, with strong uptake among type 2 diabetes users.
2. Prescriber Base Expansion
The company expanded its US prescriber network to over 30,000 healthcare professionals, representing a 28% year-over-year increase. Balanced volume gains from both the US and international markets were driven largely by patients transitioning from multiple daily injections.
3. R&D Investment and Margins
Heavy investment in research and development is designed to support future innovation but may pressure near-term margins. Leadership noted that pod usage data better reflects revenue trends than script fill counts, which can vary by seasonality.
4. Future Growth Drivers
Insulet plans to introduce a fully closed-loop insulin delivery system by 2028 to expand its addressable market into primary care. The Omnipod 5’s compatibility with the 15-day Dexcom G7 sensor enhances its integration strategy and competitive positioning.